SCHEMBL2927992

SCHEMBL2927992

COc1cc(C(=O)NC2CNC2)ccc1Nc1cncc(-c2cc3cc(F)ccc3[nH]2)n1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.40
HPGD P15428 1/20 0.40
TSHR P16473 1/20 0.40
LRRK2 Q5S007 5/20 0.39
MLLT1 Q03111 1/20 0.39
CCNA2 P20248 1/20 0.39
CDK2 P24941 1/20 0.39
TTK P33981 1/20 0.39
AURKA O14965 1/20 0.39
AURKB Q96GD4 1/20 0.39
PTK2 Q05397 3/20 0.39
BRAF P15056 2/20 0.38
JAK1 P23458 1/20 0.38
TYK2 P29597 1/20 0.38
IGF1R P08069 1/20 0.38
KDR P35968 1/20 0.37
BRD4 O60885 1/20 0.37
BRDT Q58F21 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL2928643 0.96 PTK2 (0.39) ALDH1A1HPGDTSHRLRRK2MLLT1
SCHEMBL13515312 0.94 KDR (0.46) ALDH1A1HPGDTSHRLRRK2MLLT1
SCHEMBL4244323 0.89 PTK2 (0.39) ALDH1A1HPGDTSHRLRRK2MLLT1
SCHEMBL2932358 0.89 IGF1R (0.39) ALDH1A1HPGDTSHRLRRK2MLLT1
SCHEMBL2928408 0.88 PIM3 (0.46) LRRK2CCNA2CDK2TTKAURKA
SCHEMBL2935096 0.86 ADORA2A (0.38) LRRK2CCNA2CDK2TTKAURKA
SCHEMBL14269675 0.85 TTK (0.43) LRRK2CCNA2CDK2TTKBRAF
SCHEMBL2930653 0.85 TMEM97 (0.43) LRRK2CCNA2CDK2TTK
SCHEMBL2933090 0.83 KDR (0.53) ALDH1A1HPGDTSHRLRRK2PTK2
SCHEMBL2925991 0.83 KDR (0.53) ALDH1A1HPGDTSHRLRRK2PTK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2044051-B1 PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS BIOVITRUM AB PUBL (SE) 2010-01-27 EP claimed
EP-2044051-A1 PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS BIOVITRUM AB (publ) (SE) 2009-04-08 EP claimed
US-20080039450-A1 Compounds BIOVITRUM AB (PUBL.) (SE) 2008-02-14 US claimed
WO-2007147874-A1 PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS BIOVITRUM AB (PUBL) (SE) 2007-12-27 WO claimed
EP-2044051-B1 PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS BIOVITRUM AB PUBL (SE) 2010-01-27 EP disclosed
WO-2007147874-A1 PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS BIOVITRUM AB (PUBL) (SE) 2007-12-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080039450-A1 Compounds NEK2, CSNK2A3, CSNK2A1 ALDH1A1 3748/4885HPGD 3066/4885TSHR 2982/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.